Q3 2025 Investor Presentation November 6th, 2025 1 Disclaimer General. This presentation (this "Presentation") is provided solely for informational purposes. This Presentation is subject to update, completion, revision, verification and further amendment without notice. None of Abacus Global Management, Inc. (the "Company", "Abacus", Abacus Global Management", "we", "our", or "us") or its affiliates has authorized anyone to provide interested parties with additional or different information. The information ...

Financial Performance - Q2 2025 - Total revenue nearly doubled, reaching $56.2 million compared to $29.1 million in the prior-year period, representing a 93% increase[54] - Adjusted Net Income increased to $21.9 million, compared to $11.7 million, and Adjusted EBITDA increased to $31.5 million, compared to $16.7 million in the prior-year period[54] - GAAP Net Income attributable to shareholders was $17.6 million, compared to $0.7 million in the prior-year period[54] - Assets Under Management (AUM) reached $3.3 billion[17,56] Growth & Capital Deployment - Capital deployed for policy purchases in Q2 2025 amounted to $121.8 million[31,56] - Longevity Funds attracted $123.1 million in capital inflows for the quarter, with the ETFs seeing a +9% increase in growth in AUM compared to the prior quarter[54] - Year-over-year growth in capital deployed totaled $142 million, representing a 16% increase[19] ABL Tech - Mortality Tracking - ABL Tech's mortality tracking system now covers 2,033,198 lives in Q2 2025[46] - ABL Tech experienced a 17x year-over-year increase in lives tracked[44] FY 2025 Guidance - The company raised its Adjusted Net Income guidance for FY 2025 to a range of $74 million to $80 million, implying a +59% to +72% year-over-year change[58]